At the presentation of the financial results for the quarter ended 30 June 2019, Kenneth T. Mills, President and CEO of the clinical-stage biotechnology company REGENXBIO Inc., said:
“We recently announced the expansion of our pipeline using NAV Vectors to deliver therapeutic antibodies, beginning with novel treatments for HAE. This approach has enormous potential for patients who lack treatments or who are currently underserved by existing therapies. We currently have an internal pipeline of novel gene therapy candidates across large, chronic diseases and rare, monogenic diseases, which positions us to potentially develop meaningful treatments for a broad spectrum of patients with significant unmet needs.”
(Source: REGENXBIO)
